Calliditas Therapeutics AB (Calliditas Therapeutics AB) Change In Receivables : $0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Change In Receivables?

Calliditas Therapeutics AB's change in receivables for the quarter that ended in Dec. 2023 was $0.00 Mil. It means Calliditas Therapeutics AB's Accounts Receivable stayed the same from Sep. 2023 to Dec. 2023 .

Calliditas Therapeutics AB's change in receivables for the fiscal year that ended in Dec. 2023 was $-17.80 Mil. It means Calliditas Therapeutics AB's Accounts Receivable increased by $17.80 Mil from Dec. 2022 to Dec. 2023 .

Calliditas Therapeutics AB's Accounts Receivable for the quarter that ended in Dec. 2023 was $17.64 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Calliditas Therapeutics AB's Days Sales Outstanding for the three months ended in Dec. 2023 was 36.55.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Calliditas Therapeutics AB's liquidation value for the three months ended in Dec. 2023 was $-39.47 Mil.

Calliditas Therapeutics AB Change In Receivables Historical Data

The historical data trend for Calliditas Therapeutics AB's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Change In Receivables Chart

Calliditas Therapeutics AB Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-5.68

0.96

-1.29

-8.85

-17.80

Calliditas Therapeutics AB Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Calliditas Therapeutics AB Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Calliditas Therapeutics AB (NAS:CALT) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Calliditas Therapeutics AB's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	17.635	/	44.022	*	91
=	36.55

2. In Ben Graham's calculation of liquidation value, Calliditas Therapeutics AB's accounts receivable are only considered to be worth 75% of book value:

Calliditas Therapeutics AB's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	94.928	-	148.616	+	0.75 * 17.635	+	0.5 * 1.991
=	-39.47

Calliditas Therapeutics AB Change In Receivables Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

CALTX:Sweden CALTXs:UK LC8:Germany

Address

Kungsbron 1, D5, Stockholm, SWE, SE-111 22

Website

https://www.calliditas.se

Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.